HilleVax Inc. (HLVX)
undefined
undefined%
At close: undefined
2.09
0.00%
After-hours Jan 06, 2025, 05:39 PM EST

Company Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines.

It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

The company is headquartered in Boston, Massachusetts.

HilleVax Inc.
HilleVax Inc. logo
Country United States
IPO Date Apr 29, 2022
Industry Biotechnology
Sector Healthcare
Employees 90
CEO Dr. Robert M. Hershberg M.D., Ph.D.

Contact Details

Address:
75 State Street
Boston, Massachusetts
United States
Website https://www.hillevax.com

Stock Details

Ticker Symbol HLVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001888012
CUSIP Number 43157M102
ISIN Number US43157M1027
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Robert M. Hershberg M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Chairman of the Board
Dr. Anju Chatterji Ph.D. Chief Technology Officer
Shane A. Maltbie Chief Financial Officer & Treasurer
Dr. Aditya Kohli Ph.D. Co-Founder & Director
Ozzie Berger Senior Vice President of Regulatory Affairs
Paul S. Bavier J.D. General Counsel, Secretary & Chief Administrative Officer

Latest SEC Filings

Date Type Title
Dec 05, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 10-Q Quarterly Report
Nov 07, 2024 8-K Current Report
Oct 16, 2024 8-K Current Report
Aug 09, 2024 10-Q Quarterly Report
Aug 09, 2024 8-K Current Report
Jul 31, 2024 8-K Current Report
Jul 23, 2024 8-K Current Report